Principal Investigator
Leonel Hernandez Aya
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20220984
Clinical Trial Summary
Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine IMA203-101)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
+1 (407) 7659589